- Conditions
- Allergy
- Interventions
- Placebo, Xolair
- Drug
- Lead sponsor
- Creighton University
- Other
- Eligibility
- 19 Years to 50 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 112
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD), Allergies
- Interventions
- Omalizumab (Xolair®), Sodium Chloride (NaCl) 0.9 %
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 334 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Tucson, Arizona • San Francisco, California + 16 more
- Conditions
- Asthma
- Interventions
- Omalizumab, Placebo
- Drug
- Lead sponsor
- Creighton University
- Other
- Eligibility
- 16 Years to 50 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Allergic Asthma
- Interventions
- Omalizumab
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Food Allergy, Food Allergy in Children
- Interventions
- Omalizumab Injection
- Drug
- Lead sponsor
- National Jewish Health
- Other
- Eligibility
- 1 Year to 55 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Asthma
- Interventions
- Omalizumab
- Drug
- Lead sponsor
- University of Mississippi Medical Center
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Jackson, Mississippi
- Conditions
- Idiopathic Angioedema
- Interventions
- Omalizumab, Placebos
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- Tezepelumab Dose 1, Tezepelumab Dose 2, Omalizumab, Placebo
- Biological
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Fountain Valley, California • Laguna Niguel, California + 21 more
- Conditions
- Bullous Pemphigoid
- Interventions
- Rituximab combined with Omalizumab
- Drug
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years to 90 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Anaphylaxis, Hypotension, Bronchospasm, Angioedema
- Interventions
- Epinephrine, Omalizumab (Xolair), Placebos
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2019
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Allergies, Food Allergy
- Interventions
- 5mg/kg omalizumab injection, 15mg/kg omalizumab injection
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 1 Year to 55 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Chapel Hill, North Carolina • Dallas, Texas
- Conditions
- Asthma
- Interventions
- Omalizumab
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 6 Years to 20 Years
- Enrollment
- 224 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • New York, New York • Cleveland, Ohio + 1 more
- Conditions
- Asthma
- Interventions
- omalizumab, Placebo
- Drug · Other
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Chronic Idiopathic Urticaria
- Interventions
- Omalizumab, Placebo, H1 antihistamine, H2 antihistamine, leukotriene receptor antagonist, Diphenhydramine
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 336 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 40
- States / cities
- Scottsdale, Arizona • Mission Viejo, California • Napa, California + 35 more
- Conditions
- Allergic Asthma
- Interventions
- Xolair
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Valrico, Florida • Hinsdale, Illinois + 4 more
- Conditions
- Eosinophilic Disorder, Food Allergy
- Interventions
- Entero-tracker, omalizumab, dupliumab
- Device · Biological
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 5 Years to 55 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Asthma
- Interventions
- Omalizumab, Placebo, Fluticasone
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 6 Years to 11 Years
- Enrollment
- 628 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 56
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Huntington Beach, California + 48 more
- Conditions
- Asthma
- Interventions
- Xolair
- Drug
- Lead sponsor
- University of Mississippi Medical Center
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Jackson, Mississippi
- Conditions
- Asthma in Children, Atopy, Viral Upper Respiratory Infection
- Interventions
- Omalizumab, Placebo
- Drug
- Lead sponsor
- Children's National Research Institute
- Other
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Asthma
- Interventions
- Not listed
- Lead sponsor
- National Jewish Health
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Peanut Allergy
- Interventions
- Omalizumab
- Drug
- Lead sponsor
- Lynda Schneider
- Other
- Eligibility
- 7 Years to 25 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Urticaria
- Interventions
- Xolair® (Omalizumab)
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Hay Fever, Hypersensitivity, Allergy, Rhinitis
- Interventions
- omalizumab, Placebo omalizumab, Ragweed rush immunotherapy (RIT), Placebo rush immunotherapy (RIT), Ragweed immunotherapy (IT), Placebo immunotherapy (IT)
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 3
- States / cities
- Iowa City, Iowa • Omaha, Nebraska • Madison, Wisconsin
- Conditions
- Food Allergy
- Interventions
- Omalizumab, Food Flour Allergens
- Drug
- Lead sponsor
- Andrew Long, PharmD
- Other
- Eligibility
- 2 Years to 25 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Mountain View, California